Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded by Royal Bank Of Canada to Hold

Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research note issued on Thursday, Zacks reports.

Other equities research analysts have also issued reports about the company. Robert W. Baird lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $40.00 to $16.00 in a research report on Thursday. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating on the stock in a research note on Thursday. Jefferies Financial Group dropped their target price on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a report on Thursday. TD Cowen reduced their target price on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $37.53.

Ultragenyx Pharmaceutical Trading Down 44.0%

Shares of NASDAQ RARE opened at $14.85 on Thursday. Ultragenyx Pharmaceutical has a 12-month low of $13.81 and a 12-month high of $39.89. The stock has a market cap of $1.46 billion, a PE ratio of -2.54 and a beta of 0.31. The company has a 50-day moving average of $28.07 and a 200 day moving average of $25.04.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same period last year, the company posted ($1.17) EPS. The business’s revenue was up 28.5% on a year-over-year basis. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -3.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in RARE. BlackRock Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $355,746,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $6,397,000. Deutsche Bank AG acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $5,503,000. Corient Private Wealth LP purchased a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $4,644,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $6,098,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see potential value after the selloff. Jefferies, Citi, TD Cowen, Canaccord, Cantor Fitzgerald and HC Wainwright retained buy or overweight ratings, although they substantially reduced their price targets. Ultragenyx stock downgraded trial setback
• Positive Sentiment: Ultragenyx’s commercial rare-disease portfolio remains an important potential support for the business, and commentary highlighted the possibility that the company could recover if marketed products continue to grow. Ultragenyx Stock Sinks on Drug Trial Failure
• Positive Sentiment: Unusually heavy call-option activity and speculative comments that Ultragenyx could become a takeover target, including by larger rare-disease companies, offered a possible source of near-term support but do not represent confirmed corporate activity.
• Neutral Sentiment: Analyst views became sharply more cautious: Wells Fargo, JPMorgan, Baird, Evercore, William Blair and Bank of America downgraded the stock or moved to more conservative ratings. Revised targets ranged from $16 to $37, indicating significant uncertainty despite implied upside from the recent price.
• Neutral Sentiment: Management is expected to evaluate “significant” cost reductions and reconsider the future of the Angelman syndrome program, which could preserve cash but also reduce research investment. Ultragenyx to weigh significant cost cuts
• Negative Sentiment: The Aspire study failed to achieve both its primary endpoint—change in Bayley-4 cognitive raw score—and key secondary endpoint, the Multidomain Responder Index. The results place apazunersen’s regulatory and commercial prospects in serious doubt. Ultragenyx Announces Phase 3 Aspire Results
• Negative Sentiment: The late-stage failure triggered a broad analyst reset and raised concerns about Ultragenyx’s pipeline concentration, future revenue growth and continued cash burn. Ultragenyx shares crater after Angelman syndrome drug fails

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.